Relative Risk (RR) of PTLD by Method of T-Cell Depletion of the Bone Marrow
| Method of T-Cell Depletion . | No. of PTLD . | RR4-150 . | 95% CI . |
|---|---|---|---|
| No T-cell depletion | 36 | 1.0 | Reference |
| Anti-T or anti-T + NK MoAb4-151 | 31 | 12.3 | 7.1-21.3 |
| SRBC rosetting‡ | 5 | 15.6 | 5.3-37.5 |
| Lectins4-153 | 1 | 4.1 | 0.2-19.8 |
| CAMPATH-1 MoAb | 2 | 2.0 | 0.3-6.7 |
| Elutriation/density gradient centrifugation4-155 | 1 | 2.6 | 0.1-12.4 |
| Unclassified/unknown | 2 | 12.7 | 2.0-43.1 |
| Method of T-Cell Depletion . | No. of PTLD . | RR4-150 . | 95% CI . |
|---|---|---|---|
| No T-cell depletion | 36 | 1.0 | Reference |
| Anti-T or anti-T + NK MoAb4-151 | 31 | 12.3 | 7.1-21.3 |
| SRBC rosetting‡ | 5 | 15.6 | 5.3-37.5 |
| Lectins4-153 | 1 | 4.1 | 0.2-19.8 |
| CAMPATH-1 MoAb | 2 | 2.0 | 0.3-6.7 |
| Elutriation/density gradient centrifugation4-155 | 1 | 2.6 | 0.1-12.4 |
| Unclassified/unknown | 2 | 12.7 | 2.0-43.1 |
Relative risks were adjusted for HLA disparity, use of ATG or MoAb anti-CD3 A641 for acute GVHD, occurrence of acute GVHD II-IV, occurrence of extensive chronic GVHD, and radiation conditioning.
Anti-T methods include monoclonal antibodies directed against T-cell–specific epitopes (including single antibodies or combinations): CD3, CD3/CD7, CD4, CD4/CD8, CD4/CD5/CD8, CD5, CD5/CD8, CD5/ricin, T10 B9, CD6/CD7/CD8, CD6/CD7, CD6/CD8, CD8, CD7/CD8. Anti-T and anti-NK methods include monoclonal antibodies directed against T-cell– and NK-cell–specific epitopes (including single antibodies or combinations): CD2, CD2/CD3, CD2/CD8, CD2/CD4/CD8, CD2/CD6/CD8/CD28, CD2/CD7, CD2/CD5/CD7, CD2/CD5, CD8, CD2/CD3/CD8, CD2/CD8, ATG incubation.
SRBC (sheep red blood cell) rosetting methods includes SRBC rosetting + density gradient centrifugation.
Lectin methods include lectin or lectin and E-rosetting (n = 126), and lectin and MoAb CD5/CD8 (n = 7).
Elutriation methods include elutriation, density gradient centrifugation, and elutriation/density gradient centrifugation.